Torsten Hertrampf
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Torsten Hertrampf has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Patrick Diel
4 shared publications- Gisela H. Degen
Leibniz Research Centre for Working Environment and Human Factors (IfADo), Dortmund, Germany
2 shared publications - Jan Seibel
Abbott GmbH & Co. KG, Preclinical Safety, D-67061 Ludwigshafen, Germany
2 shared publications - Karl Heinrich Fritzemeier
University of Essen-Duisburg, Universitätsstraße 2, 45141 Essen, Germany
2 shared publications Ute Laudenbach-Leschowsky
2 shared publicationsAbdel Ait Kaid
1 shared publication
Latest Publications
- 1 June 2010
- Published by The Endocrine Society
- p. P1-45
Analysis of the Effects of Androgens and Training on Myostatin Propeptide and Follistatin Concentrations in Blood and Skeletal Muscle Using Highly Sensitive Immuno PCR.
Myostatin propeptide (MYOPRO) and follistatin (FOLLI) are potent myostatin inhibitors. In this study we analysed long-term training effects and effects of androgens on MYOPRO and FOLLI concentrations in blood and skeletal muscle using highly sensitive Immuno PCR. To study training effects in humans young healthy males did either a 3-month endurance-training or a strength-training. Blood and biopsy samples were analysed. Our data revealed that training did not significantly affect MYOPRO and FOLLI concentrations in serum and muscle. To investigate whether total skeletal muscle mass may affect circulating MYOPRO and FOLLI levels, blood samples of tetraplegic patients, untrained volunteers and bodybuilders were analysed. Interestingly, serum levels of MYOPRO were significantly increased in the bodybuilder group. To investigate the effects of androgens on MYPRO and FOLLI levels, orchiectomised rats were treated with Testosterone. MYOPRO was increased in blood and muscle. In summary Immuno PCR analysis demonstrate that moderate training does not affect the concentrations of MYOPRO to FOLLI. In contrast androgen treatment results in a significant increase of MYOPRO in the skeletal muscle and also in serum. This observation provides insights into the molecular mechanisms of anabolic activity of androgens. In addition it could serve as a basis for a test system to detect abuse of myostatin inhibitors. Sources of Research Support: World Anti Doping Agency WADA. Nothing to Disclose: PD, TS, SG, TH, SM, SS, FW, MA
- 1 June 2010
- Published by The Endocrine Society
- p. P1-45
Analysis of the Effects of Androgens and Training on Myostatin Propeptide and Follistatin Concentrations in Blood and Skeletal Muscle Using Highly Sensitive Immuno PCR.
Myostatin propeptide (MYOPRO) and follistatin (FOLLI) are potent myostatin inhibitors. In this study we analysed long-term training effects and effects of androgens on MYOPRO and FOLLI concentrations in blood and skeletal muscle using highly sensitive Immuno PCR. To study training effects in humans young healthy males did either a 3-month endurance-training or a strength-training. Blood and biopsy samples were analysed. Our data revealed that training did not significantly affect MYOPRO and FOLLI concentrations in serum and muscle. To investigate whether total skeletal muscle mass may affect circulating MYOPRO and FOLLI levels, blood samples of tetraplegic patients, untrained volunteers and bodybuilders were analysed. Interestingly, serum levels of MYOPRO were significantly increased in the bodybuilder group. To investigate the effects of androgens on MYPRO and FOLLI levels, orchiectomised rats were treated with Testosterone. MYOPRO was increased in blood and muscle. In summary Immuno PCR analysis demonstrate that moderate training does not affect the concentrations of MYOPRO to FOLLI. In contrast androgen treatment results in a significant increase of MYOPRO in the skeletal muscle and also in serum. This observation provides insights into the molecular mechanisms of anabolic activity of androgens. In addition it could serve as a basis for a test system to detect abuse of myostatin inhibitors. Sources of Research Support: World Anti Doping Agency WADA. Nothing to Disclose: PD, TS, SG, TH, SM, SS, FW, MA
- 28 April 2006
- Published by Georg Thieme Verlag KG in Planta Medica
- Vol. 72 (06) , 484-487
Combined Effects of Physical Activity, Dietary Isoflavones and 17β-Estradiol on Movement Drive, Body Weight and Bone Mineral Density in Ovariectomized Female Rats
Reduced estrogen levels occurring during menopause in woman are accompanied by a variety of disorders, e. g., hot flushes, depressions, osteoporosis, increase of body weight, and reduced movement drive. In this study we investigated the combined effects of physical activity, estradiol substitution, and a phytoestrogen-rich diet on bone mineral density, increase of body weight, and movement drive in an animal model. Ovariectomized (OVX) female Wistar rats were either fed an isoflavone-rich diet (IRD) or substituted with 17β-estradiol (E2) for 3 months. Sham-operated rats (Sham) and vehicle-treated OVX animals served as controls. One half of the animals had the opportunity of voluntary wheel running. OVX rats displayed an eight times lower movement activity than Sham animals. E2 treatment, but not IRD, significantly increased the movement activity of OVX rats. During 3 months the lowest increase of body weight was observed in Sham animals, the highest rate in OVX animals. Along with running activity E2 treatment, but not IRD, also lowered the increase of body weight significantly compared to OVX animals. Bone mineral density (BMD) in the trabecular area of the tibia was strongly reduced in OVX rats compared to Sham animals. In contrast to IRD, E2 substitution resulted in a protection of BMD in this area compared to OVX animals. Our data demonstrate that body weight, movement drive, and BMD are positively influenced by E2. The steroid estrogen acts in the trabecular area of the tibia in a bone-protective manner, increases movement drive and antagonizes the increase of body weight. All these effects could not be observed in animals fed an isoflavone-rich diet. BMD:bone mineral density Dai:daidzein E2:17β-estradiol EE:ethinylestradiol ER:estrogen receptor Gen:genistein HRT:hormone replacement therapy IRD:isoflavone-rich diet OVX:ovariectomized ROI:region of interest
- 28 April 2006
- Published by Georg Thieme Verlag KG in Planta Medica
- Vol. 72 (06) , 484-487
Combined Effects of Physical Activity, Dietary Isoflavones and 17β-Estradiol on Movement Drive, Body Weight and Bone Mineral Density in Ovariectomized Female Rats
Reduced estrogen levels occurring during menopause in woman are accompanied by a variety of disorders, e. g., hot flushes, depressions, osteoporosis, increase of body weight, and reduced movement drive. In this study we investigated the combined effects of physical activity, estradiol substitution, and a phytoestrogen-rich diet on bone mineral density, increase of body weight, and movement drive in an animal model. Ovariectomized (OVX) female Wistar rats were either fed an isoflavone-rich diet (IRD) or substituted with 17β-estradiol (E2) for 3 months. Sham-operated rats (Sham) and vehicle-treated OVX animals served as controls. One half of the animals had the opportunity of voluntary wheel running. OVX rats displayed an eight times lower movement activity than Sham animals. E2 treatment, but not IRD, significantly increased the movement activity of OVX rats. During 3 months the lowest increase of body weight was observed in Sham animals, the highest rate in OVX animals. Along with running activity E2 treatment, but not IRD, also lowered the increase of body weight significantly compared to OVX animals. Bone mineral density (BMD) in the trabecular area of the tibia was strongly reduced in OVX rats compared to Sham animals. In contrast to IRD, E2 substitution resulted in a protection of BMD in this area compared to OVX animals. Our data demonstrate that body weight, movement drive, and BMD are positively influenced by E2. The steroid estrogen acts in the trabecular area of the tibia in a bone-protective manner, increases movement drive and antagonizes the increase of body weight. All these effects could not be observed in animals fed an isoflavone-rich diet. BMD:bone mineral density Dai:daidzein E2:17β-estradiol EE:ethinylestradiol ER:estrogen receptor Gen:genistein HRT:hormone replacement therapy IRD:isoflavone-rich diet OVX:ovariectomized ROI:region of interest
- 20 January 2006
- Published by Georg Thieme Verlag KG in Planta Medica
- Vol. 72 (4) , 304-310
Effects of Genistein on the Mammary Gland Proliferation of Adult Ovariectomised Wistar Rats
The effects of phytoestrogens on the female breast are discussed controversially. On the one hand, epidemiological and experimental data provide evidence that dietary phytoestrogens may prevent the development of breast cancer. On the other hand, in breast cancer cell lines and tumour models isoflavone phytoestrogens have been demonstrated to stimulate the growth of estrogen-dependent breast cancer cells. To further investigate the molecular effects of genistein (Gen) on the mammary gland, we treated non-tumour bearing, ovariectomised female Wistar rats with this phytoestrogen either subcutaneously (10 mg/kg body weight) or orally (100 and 200 mg/kg body weight) for 3 days. Estradiol (E2, 0.004 mg/kg s. c.) and ethynylestradiol (EE, 0.1 mg/kg per os) served as reference compounds. In the breast tissue, mRNA and protein expression of the progesterone receptor (marker for estrogenicity) and PCNA (marker gene for proliferation) were examined by quantitative real-time PCR, Western blotting and immunohistochemistry; the uterotrophic response was assessed also. Treatment with Gen per os or s. c. results in a small but significant stimulation of the uterine wet weight. In the mammary gland, Gen stimulates the expression of progesterone receptor (PR) but, in contrast to E2, the isoflavone does not stimulate the expression of PCNA. These findings resemble recent data demonstrating a differential ability of Gen to induce uterine gene expression and uterine proliferation. Our data indicate that in non-malignant breast tissue short-term administration of Gen, in contrast to more potent estrogens like E2, does not induce proliferation. Chronic stimulation of proliferation is believed to be a key mechanism during the development of breast cancer. The limited ability of Gen to stimulate proliferation in this tissue could be an indication for a limited carcinogenic potency of Gen in the breast. In further investigations it is important to identify molecular differences between healthy and malignant breast tissue which may explain the different sensitivity towards Gen treatment. Gen:genistein PCNA:proliferating cell nuclear antigen E2:17β-estradiol ER:estrogen receptor EE:ethynylestradiol PR:progesterone receptor HRT:hormone replacement therapy OVX:ovariectomised
- 20 January 2006
- Published by Georg Thieme Verlag KG in Planta Medica
- Vol. 72 (4) , 304-310
Effects of Genistein on the Mammary Gland Proliferation of Adult Ovariectomised Wistar Rats
The effects of phytoestrogens on the female breast are discussed controversially. On the one hand, epidemiological and experimental data provide evidence that dietary phytoestrogens may prevent the development of breast cancer. On the other hand, in breast cancer cell lines and tumour models isoflavone phytoestrogens have been demonstrated to stimulate the growth of estrogen-dependent breast cancer cells. To further investigate the molecular effects of genistein (Gen) on the mammary gland, we treated non-tumour bearing, ovariectomised female Wistar rats with this phytoestrogen either subcutaneously (10 mg/kg body weight) or orally (100 and 200 mg/kg body weight) for 3 days. Estradiol (E2, 0.004 mg/kg s. c.) and ethynylestradiol (EE, 0.1 mg/kg per os) served as reference compounds. In the breast tissue, mRNA and protein expression of the progesterone receptor (marker for estrogenicity) and PCNA (marker gene for proliferation) were examined by quantitative real-time PCR, Western blotting and immunohistochemistry; the uterotrophic response was assessed also. Treatment with Gen per os or s. c. results in a small but significant stimulation of the uterine wet weight. In the mammary gland, Gen stimulates the expression of progesterone receptor (PR) but, in contrast to E2, the isoflavone does not stimulate the expression of PCNA. These findings resemble recent data demonstrating a differential ability of Gen to induce uterine gene expression and uterine proliferation. Our data indicate that in non-malignant breast tissue short-term administration of Gen, in contrast to more potent estrogens like E2, does not induce proliferation. Chronic stimulation of proliferation is believed to be a key mechanism during the development of breast cancer. The limited ability of Gen to stimulate proliferation in this tissue could be an indication for a limited carcinogenic potency of Gen in the breast. In further investigations it is important to identify molecular differences between healthy and malignant breast tissue which may explain the different sensitivity towards Gen treatment. Gen:genistein PCNA:proliferating cell nuclear antigen E2:17β-estradiol ER:estrogen receptor EE:ethynylestradiol PR:progesterone receptor HRT:hormone replacement therapy OVX:ovariectomised